Chinese Covid-19 vaccine could be tested, manufactured in Canada

The research council said on Tuesday, China's CanSino Biologics Inc, the company behind one of the few coronavirus vaccine candidates already in clinical trials, is collaborating with Canada's National Research Council to "pave the way" for future experiments in Canada.

The NRC stated it would climb a production process for CanSino's vaccine at a government facility in Montreal, and that CanSino was preparing a trial application for drug regulator Health Canada.

If Cansino's vaccine works, the collaboration could help ensure that Canadians have access to it. Local trial data could convince Health Canada that the vaccine is safe, and local manufacturing could ensure some doses are at hand.

Asked whether the collaboration would make it possible for Health Canada to consider data gathered in China, NRC said that in general, data could be shared with the regulator's approval.

The agency stated, "Canadian clinical trials will increase on Chinese data and provide an improved understanding of the vaccine candidate's safety profile."

A vaccine that protects people from the coronavirus could end the pandemic, but finding one that works and manufacturing enough doses is a considerable challenge.

Relations between Canada and China have been strained since Canadian authorities arrested Huawei Chief Financial Officer Meng Wanzhou on December 1, 2018, at the request of the United States. Her arrest angered the Chinese government, which finally detained two Canadian citizens - Michael Kovrig and Michael Spavor - on state security charges.

But amid the pandemic, Canada has struggled to import protective equipment from the United States, turning in part to suppliers in China. A federal appropriation website notes that Canada has "established on-the-ground support in China" to manage bulk purchases.

CanSino and the NRC have worked together since 2013, and the company's vaccine is produced using a cell line that was developed at the NRC, the agency added.

CanSino Chairman Xuefeng Yu worked in Canada from 1996 to 2009, according to the company's website, mainly for Sanofi.

Shares of Hong Kong-listed CanSino began on April 26 after the company said Health Canada had agreed to meet to discuss a clinical trial application.

Separately on Tuesday, Canada promised C$600 million to replenish the GAVI vaccine alliance, to support routine vaccinations around the world. GAVI is also helping low-income countries respond to coronavirus outbreaks.